Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, FRI

ScriptsMD Makes Semaglutide Weight Loss Treatment Accessible and Affordable


DELRAY BEACH, Fla., Nov. 4, 2024 /PRNewswire/ -- ScriptsMD is an innovative healthcare solution that provides Americans with affordable access to semaglutide weight loss treatment while addressing nationwide medication shortages. The company's comprehensive program delivers semaglutide at just $239 monthly*, making effective weight management accessible to more Americans in a landscape where similar treatments often cost three to four times more.

*Prices subject to change.

Recent clinical studies conducted by The New England Journal of Medicine demonstrate semaglutide's remarkable effectiveness, with participants losing an average of 14.9% body weight over a 68-week trial period. Through ScriptsMD's streamlined telehealth platform, patients can access this proven treatment at just $7.97 daily, including medication, consultation, and support.

ScriptsMD's all-inclusive program provides:

The company's efficient process begins with a 5-minute online health questionnaire to ensure comprehensive patient evaluation. Qualified patients receive prescriptions in 1-3 days, with medication delivered in 1-2 days through temperature-controlled shipping. This acute, personalized attention helps patients start their weight loss journey without delay.

According to The University of Pennsylvania, as many as 5 million Americans were prescribed Semaglutide in 2023. ScriptsMD distinguishes itself through transparent pricing with no insurance requirements or hidden fees. The program maintains consistent monthly pricing regardless of dosage, up to 1.5mg weekly, backed by a 100% satisfaction guarantee. Treatment is managed through a secure, LegitScript-certified platform with McAfee protection, ensuring patient privacy and data security.

For more information about ScriptsMD's Semaglutide program and telehealth services, visit ScriptsMD.

ScriptsMD is revolutionizing healthcare access through its telehealth platform. By connecting patients with board-certified physicians and providing affordable medication access, ScriptsMD makes quality healthcare more accessible to Americans. The company's commitment to patient care includes 24/7 support, transparent pricing, and comprehensive treatment programs.

Media Contact
[email protected]

SOURCE Scripts MD


These press releases may also interest you

at 12:55
Vertex Presents Positive Long-Term Data On CASGEVYtm (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Five-Year Results Confirm Genentech's Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...

at 12:35
bluebird bio Presents Positive Long-Term Data On LYFGENIAtm (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
bluebird bio, Inc. today announced new and updated data from LYFGENIAtm (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at...

at 12:05
ReAlta Life Sciences Announces Positive Preclinical Data for RLS-0071 (pegtarazimod) in Acute Graft-Versus-Host Disease (aGVHD) at American Society of Hematology Annual Meeting
ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced positive...

at 12:05
Apple Sued for Knowingly Hosting Child Sexual Abuse Material on Its Products, Failing to Protect Survivors
This weekend, a class action lawsuit was filed against Apple on behalf of thousands of survivors of child sexual abuse for knowingly allowing the storage of images and videos documenting their abuse on iCloud and the company's defectively designed...

More news about Science and technology...


News published on and distributed by: